Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKOVE-1 of NVL-655 in ALK-positive advanced NSCLC and other solid tumors
jRCT2031240335Phase 2Recruiting
- Sponsor
- Nuvalent
- Start
- Oct 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of neladalkib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (7 arms), sponsored by Nuvalent. Primary endpoints: Dose limiting toxicities, Recommended Phase 2 Dose and 2 more. Started Oct 2024; status: recruiting.
02
Drugs
neladalkib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031240335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240335.